Financial Performance - For the fiscal year ending December 31, 2025, the company reported revenue of approximately RMB 14.26 billion, representing a year-on-year growth of about 20.8%[4] - The company's profit for the period was approximately RMB 1.06 billion, a year-on-year decline of about 18.5%[10] - Adjusted net profit, excluding non-cash share-based payment expenses, was approximately RMB 1.53 billion, an increase of about 1.3% compared to the previous year[10] - The group's total revenue for the review period was approximately RMB 14,256,171 thousand, representing a year-on-year growth of about 20.8% compared to RMB 11,798,662 thousand in 2024[38] - Gross profit for the review period was approximately RMB 4,856,879 thousand, an increase of about 10.1% from RMB 4,411,969 thousand in 2024, with a gross margin of approximately 34.1%[38][45] - Net profit for the review period was approximately RMB 1,061,599 thousand, down about 18.5% from RMB 1,303,255 thousand in 2024[38] - The group's profit before tax was approximately RMB 1,475,684 thousand, a decrease of about 10.8% compared to RMB 1,655,043 thousand in 2024[38] Revenue Breakdown - The ToB business contributed approximately RMB 11.34 billion in revenue, with a year-on-year increase of about 21.7%[8] - The self-branded business generated revenue of approximately RMB 2.912 billion, with a year-on-year growth of about 17.6%[19] - Revenue from the proprietary brand business was approximately RMB 2,911,738 thousand, a growth of about 17.6% from RMB 2,475,033 thousand in 2024, accounting for approximately 20.4% of total revenue[42] - Revenue from the enterprise customer business was approximately RMB 11,344,433 thousand, an increase of about 21.7% from RMB 9,323,629 thousand in 2024, representing approximately 79.6% of total revenue[42] - The group's revenue from the ToB business in Europe and other international markets increased to approximately RMB 7.06 billion, reflecting a robust year-on-year growth of about 38.5%[17] Expenses and Costs - R&D expenses for the period were approximately RMB 1.52 billion, reflecting a decrease of about 3.1% year-on-year, indicating improved R&D efficiency[8] - Administrative expenses rose to approximately RMB 1.29 billion, an increase of about 40.6% year-on-year, primarily due to higher non-cash share-based payment expenses[9] - The cost of raw materials accounted for approximately 50.5% of total revenue, up from about 47.7% in the previous year, indicating a shift in product mix[46] - Labor costs increased to approximately 7.5% of total revenue from 6.6% in the previous year, primarily due to changes in the revenue mix[46] - Employee compensation and benefits increased from approximately RMB 542,788 thousand to about RMB 783,911 thousand, an increase of approximately 44.4%, accounting for about 5.4% of revenue compared to 4.6% last year[49] Research and Development - R&D expenditure for the review period was approximately RMB 1.523 billion, a year-on-year decrease of about 3.1%, accounting for approximately 10.7% of revenue, down from 13.3% the previous year[27] - The company prioritized R&D investment in HNB products and aerosol medicine, with successful commercialization of multiple R&D projects expected by 2025[23] - The company filed a total of 2,056 new patent applications globally during the review period, including 1,306 invention patents, bringing the cumulative total to 11,309 patents[27] - R&D expenditure in electronic nicotine delivery systems was RMB 1.081 billion, representing 71.0% of total R&D spending, an increase of 4.4% from the previous year[28] Market Outlook - The global electronic vaporization equipment market is projected to grow at a compound annual growth rate (CAGR) of approximately 8.9% from 2021 to 2025[11] - The global retail sales volume of HNB products is expected to reach approximately 204.1 billion units by 2025, growing at a CAGR of about 14.1% from 2021 to 2025[12] - The global HNB market is projected to reach approximately $74.21 billion by 2030, with a compound annual growth rate (CAGR) of about 10% from 2025 to 2030[30] - The global electronic vaporization market is anticipated to reach around $97.14 billion by 2030, with a CAGR of approximately 8% from 2025 to 2030[31] Compliance and Governance - The company has adopted a securities trading code for directors and relevant employees, confirming adherence to the standards throughout the fiscal year ending December 31, 2025[117] - The company established an audit committee in compliance with listing rules, consisting of three independent non-executive directors, with Mr. Zhong Shan serving as the chairman[132] - The audit committee's responsibilities include reviewing the company's financial and accounting practices, risk management, and internal controls, ensuring compliance with relevant guidelines[134] Shareholder Information - The company plans to declare a final dividend of HKD 0.20 per ordinary share for the fiscal year ending December 31, 2025[6] - The company declared an interim dividend of HKD 0.20 per share for 2025, totaling approximately RMB 1,113,591 thousand, compared to RMB 276,785 thousand for the interim dividend of HKD 0.05 per share in 2024, indicating a significant increase[103] - The board proposed a final dividend of HKD 0.20 per share for the year ending December 31, 2025, subject to approval at the upcoming annual general meeting[121] Operational Highlights - The company optimized its production system to respond to changing global regulatory environments, enhancing overall capacity utilization[29] - The company is committed to continuous improvement of its compliance framework and risk control to ensure operational resilience and sustainable growth[29] - The company has established a shareholder communication policy to ensure effective communication with shareholders, which was reviewed and found satisfactory by the board[120]
思摩尔国际(06969) - 2025 - 年度业绩